Ipilimumab + nivolumab

DRUG3 trials

Sponsors

Vyriad, Inc., The Netherlands Cancer Institute, Novartis Pharmaceuticals

Conditions

Bladder CancerMelanomaNeuroendocrine CarcinomaNon Small Cell Lung CancerRenal Cell Carcinoma (RCC)Solid TumorUrothelial Carcinoma

Phase 1

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Active, not recruitingNCT03647163

Vyriad, Inc.Neuroendocrine Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) +1

Start: 2019-04-09End: 2025-09-30Updated: 2025-09-16

Phase 2

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

Active, not recruitingNCT05200988

The Netherlands Cancer InstituteBladder Cancer, Urothelial Carcinoma

Start: 2022-03-14End: 2027-09-05Target: 50Updated: 2024-03-18

Unknown Phase

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

CompletedNCT05714371

Novartis PharmaceuticalsMelanoma

Start: 2021-10-02End: 2022-01-27Updated: 2023-02-06

Related Papers

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

2026-02-27

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.

Journal of Clinical Oncology2024-01-201 citations

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial

Frontiers in Oncology2023-08-294 citations

Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with pembrolizumab, in patients with neuroendocrine carcinoma.

Journal of Clinical Oncology2023-01-244 citations